Amgen Inc (AMGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Amgen Inc stock (AMGN) is currently trading at $353.93. Amgen Inc PE ratio is 24.50. Amgen Inc PS ratio (Price-to-Sales) is 5.11. Analyst consensus price target for AMGN is $350.55. WallStSmart rates AMGN as Moderate Buy.
Amgen Inc (AMGN) stock price prediction for 2030: Base case $350.28. Bull case $437.85. Bear case $262.71. See full AMGN 2030 price forecast and methodology on WallStSmart.
- AMGN PE ratio analysis and historical PE chart
- AMGN PS ratio (Price-to-Sales) history and trend
- AMGN intrinsic value — DCF, Graham Number, EPV models
- AMGN stock price prediction 2025 2026 2027 2028 2029 2030
- AMGN fair value vs current price
- AMGN insider transactions and insider buying
- Is AMGN undervalued or overvalued?
- Amgen Inc financial analysis — revenue, earnings, cash flow
- AMGN Piotroski F-Score and Altman Z-Score
- AMGN analyst price target and Smart Rating
Amgen Inc
📊 No data available
Try selecting a different time range
AMGN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Amgen Inc (AMGN)
AMGN trades at a significant discount to its Graham intrinsic value of $665.50, offering a 47% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Amgen Inc (AMGN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Amgen Inc (AMGN) Key Strengths (6)
Every $100 of shareholder equity generates $106 in profit
Keeps $31 of every $100 in revenue after operating costs
Earnings per share surging 112.10% year-over-year
Keeps $21 of every $100 in revenue as net profit
85.30% of shares held by major funds and institutions
Large-cap company with substantial market presence
Amgen Inc (AMGN) Areas to Watch (4)
Very expensive at 21.6x book value
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 5.1x annual revenue
Modest revenue growth at 8.60%
Supporting Valuation Data
Amgen Inc (AMGN) Detailed Analysis Report
Overall Assessment
This company scores 70/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.8/10) while 4 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with Return on Equity at 106.10%, Operating Margin at 30.50%, Profit Margin at 21.00%. Growth metrics are encouraging with EPS Growth at 112.10%.
The Bear Case
The primary concerns are Price/Book, PEG Ratio, Price/Sales. Some valuation metrics including PEG Ratio (2.33), Price/Sales (5.11), Price/Book (21.65) suggest expensive pricing. Growth concerns include Revenue Growth at 8.60%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 106.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 8.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AMGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AMGN's Price-to-Sales ratio of 5.11x sits near its historical average of 4.69x (60th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 22% below its historical high of 6.53x set in Jul 2015, and 67% above its historical low of 3.06x in Mar 2008.
Compare AMGN with Competitors
Top DRUG MANUFACTURERS - GENERAL stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Amgen Inc (AMGN) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Amgen Inc is a mature, profitable business with steady cash generation. Revenue reached 36.8B with 9% growth year-over-year. Profit margins are strong at 21.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 106.1% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 21.0% and operating margin of 30.5% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Amgen Inc.
Bottom Line
Amgen Inc is a well-established business delivering consistent profitability with 21.0% margins. The growth phase may be slowing, but strong cash generation and operational efficiency make it suitable for investors seeking reliability over excitement.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Amgen Inc(AMGN)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.